U.S., Aug. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07763301) titled 'YMN-136 Vaccine for Patients With Advanced Hepatobiliary and Pancreatic Malignancies' on Aug. 10.
Brief Summary: This study aims to determine the safety and maximum tolerated dose (MTD) of YMN-136 vaccine through a dose escalation trial, and to investigate whether YMN-136 vaccine can assist in the treatment of patients with advanced hepatobiliary and pancreatic malignancies.
Study Start Date: Aug. 01
Study Type: INTERVENTIONAL
Condition:
Liver Cancer
Pancreatic Cancer
Biliary Tract Cancer (BTC)
Intervention:
BIOLOGICAL: YMN-136 vaccine
The YMN-136 vaccine will be administered according to the dose level assigned to each patie...